Compounds > 5-deazaaminopterin
Page last updated: 2024-11-07

5-deazaaminopterin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-Deazaaminopterin, also known as 5,8-dideazatetrahydrofolic acid (DDATHF), is a synthetic antifolate compound. Its synthesis involves modifying the pteridine ring of folic acid. It acts as an inhibitor of dihydrofolate reductase (DHFR), an enzyme crucial for the synthesis of tetrahydrofolic acid (THF), an essential coenzyme involved in various metabolic processes. DDATHF's ability to inhibit DHFR leads to the depletion of THF, disrupting nucleotide biosynthesis and ultimately inhibiting cell growth and proliferation. Due to its potent anti-proliferative effects, 5-deazaaminopterin has been extensively studied as a potential therapeutic agent in the treatment of various cancers, including leukemia, lymphoma, and solid tumors. Ongoing research focuses on optimizing its therapeutic efficacy and minimizing its potential side effects. The compound's unique structure and mechanism of action have also sparked interest in exploring its potential applications in other areas, such as antiviral therapy and autoimmune disorders.'

5-deazaaminopterin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID97272
SCHEMBL ID10983631
MeSH IDM0120591

Synonyms (7)

Synonym
80360-09-4
5-deazaaminopterin
nsc 110183
l-glutamic acid, n-(4-(((2,4-diaminopyrido(2,3-d)pyrimidin-6-yl)methyl)amino)benzoyl)-
QLPRLGAHKHCVEW-AWEZNQCLSA-N
n-[4-[(2,4-diaminopyrido[2,3-d]pyrimidine-6-yl)methylamino]benzoyl]-l-glutamic acid
SCHEMBL10983631
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methotrexate
[no description available]		2.8940dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		3.0750dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		2.3720folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
s-adenosylmethionine
5-deazafolic acid: structure given in first source		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Rheumatoid Arthritis
[description not available]		06.9910
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		01.9910
Adenocarcinoma, Basal Cell
[description not available]		01.9710
Sarcoma 180
An experimental sarcoma of mice.		01.9710
Experimental Mammary Neoplasms
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9710
Leukemia L 1210
[description not available]		01.9610